NDA 208159 · Btg Intl
Vistogard
Uridine Triacetate · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 7, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 11, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 0 recruiting
FAERS reports
125
66 serious, 30 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 31, 2026.
VISTOGARD ® is indicated for the emergency treatment of adult and pediatric patients: following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration. VISTOGARD ® is a pyrimidine analog indicated for the emergency treatment of adult and pediatric patients: following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration. ( 1 ) Limitations of use: VISTOGARD is not recommended for the non-emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs. ( 1 ) The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established. ( 1 ) Limitations of Use VISTOGARD is not recommended for the non-emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs. The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.
Mechanism: Uridine triacetate is an acetylated pro-drug of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation. Uridine competitively inhibits cell damage and cell death caused by fluorouracil. Fluorouracil is a cytotoxic antimetabolite that interferes with nucleic acid metabolism in normal and cancer cells. Cells anabolize fluorouracil to the cytotoxic intermediates 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 11, 2015 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelOrphanLabelReviewLetter
1 products under this application
- VISTOGARD · URIDINE TRIACETATE 10GM/PACKET · GRANULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Uridine Triacetate" as an intervention, any sponsor and status, largest first.
- Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic CancerPivotal-lookingCompleted
Wellstat TherapeuticsIndustry
NCT00024427 · 250 participants · Start Feb 2001 · Primary completion Feb 2006
Drug: fluorouracil; gemcitabine hydrochloride and 1 more · For: Drug/Agent Toxicity by Tissue/Organ; Pancreatic Cancer
Sites: Birmingham, Alabama; Burbank, California; Duarte, California · 29 sites in all
SWOG Cancer Research NetworkResearch network
NCT00004233 · 65 participants · Start Feb 2001 · Primary completion Jan 2007
Drug: fluorouracil; leucovorin calcium and 1 more · For: Esophageal Cancer; Gastric Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 97 sites in all
Wellstat TherapeuticsIndustry
NCT00044785 · 24 participants · Start Aug 2002
Drug: triacetyluridine; fluorouracil and 2 more · For: Solid Tumors
Sites: Baltimore, Maryland
Repligen CorporationIndustry
NCT00060515 · 12 participants
Drug: RG2133 (2',3',5'-tri-O-acetyluridine) · For: Mitochondrial Diseases
- Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic AciduriaPivotal-lookingCompleted
Wellstat TherapeuticsIndustry
NCT02110147 · 4 participants · Start Apr 2014 · Primary completion Dec 2014
Drug: uridine triacetate · For: Hereditary Orotic Aciduria
Sites: Detroit, Michigan; Pittsburgh, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- complication associated with device22
- vomiting22
- diarrhoea20
- death13
- thrombocytopenia13
- mucosal inflammation12
- nausea12
- inappropriate schedule of product administration10
- off label use10
- neutropenia9
- hypokalaemia8
- asthenia7
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 15 |
| 2017 | 18 |
| 2018 | 15 |
| 2019 | 13 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 13 |
| 2025 | 12 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Btg Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.